|
|
| MRD / Regn No. |
: 20260000576 |
Date |
: 24/06/2026 |
| Patient Name |
: Idrish Ali |
Age & Gender |
: 61 Yrs. / Male |
| Contact No. |
: 8011153176 |
UHID |
: |
| Ht / Wt / BMI |
: 165 / 61 / 22.41 |
BP S / BP D |
: 130 / 60 |
| Allergies |
: NKA |
Referred By |
: |
| |
|
|
Subjective |
: |
DM SINCE 2001,DKD |
|
Objective |
: |
NONE |
|
Analysis |
: |
A3G3 DKD,TYPE 2 DM,DISTAL SENSORY NEUROPATHY |
|
Plan |
: |
CHANGE TO SGLT2I SEMAGLUTIDE,SEE ME IN 1 MONTH,START SEMAGLUTIDE AFTER FUNDUS PHOTOGRAPH |
|
| Salient Investigations |
: |
ESR: 77 mm/hour | HEMOGLOBIN: 11.0 g/dL | MCH: 28 pg | MCHC: 32 gm % | MCV: 89 fl | PCV: 35 % | PLATELETS: 90 thou cells/ ul | RBC COUNT: 3.92 million/ul | TOTAL COUNT WBC: 5.94 Cells/cmm | TSH : 0.615 mIU/L | FASTING PLASMA GLUCOSE (FPG): 136 mg/dL | GLYCOSYLATED HEMOGLOBIN (HBA1C): 5.4 % | POST PRANDIAL GLUCOSE (2HPP): 65 mg/dL | UREA: 61 mg/dL | CREATININE: 1.89 mg/dL | URIC ACID: 7.7 | HDL HIGH DENSITY LIPOPROTEIN: 38 mg/dL | LDL LOW DENSITY LIPOPROTEIN: 64 mg/dL | TGL TRIGLYCERIDE: 121 mg/dL | TOTAL CHO/HDL RATIO: 3.1 | TOTAL CHOLESTEROL: 115 mg/dl | A\G RATIO: 1.49 g/dl | ALBUMIN (SERUM): 4.11 g/dL | ALKALINE PHOSPHOTASE: 104 IU/L | DIRECT BILIRUBIN: 0.14 mg/dl | GAMMA GLUTAMYL TRANSFERASE (GGT): 38 U/L | GLOBULIN: 2.76 g/dl | INDIRECT BILIRUBIN: 0.17 | SGOT (AST): 50 U/L | SGPT (ALT): 85 IU/L | TOTAL BILIRUBIN: 0.31 mg/dL | TOTAL PROTEIN: 6.87 g/dl | EGFR EGLOMERULAR FILTRATION RATE: 38.81 mL/min/1.73m2 | EGFR EGLOMERULAR FILTRATION RATE: 38.81 mL/min/1.73m2 | EGFR EGLOMERULAR FILTRATION RATE: 38.81 mL/min/1.73m2 | FIB4: 3.68 | FIB4: 3.68 | CHLORIDE: 11018 meq/L | POTASSIUM: 5.3 meQ/L | SODIUM: 139 meq/L | CALCIUM: 8.9 mg/DL | MICROALBUMIN CREATININE RATIO: 909.33 mcg/mg | VLDL: 24 mg/dl |
|
|
S# |
Generic (Trade) Name |
Route |
Dosage |
Usage |
Duration |
|
1 |
INJECTION DEGLUDEC / ASPART (INJ U100) 70/30
RYZODEG
Medicine For DIABETES |
SQ |
0-12-0 UNITS |
BEFORE FOOD
|
TILL NEXT VISIT |
| MAY CAUSE HYPOGLYCEMIA | |
|
2 |
INJECTION SEMAGLUTIDE 0,25 MG
OBEDA
Medicine For DIABETES HEART AND KIDNEY PROTECTION |
SQ |
ONCE A WEEK |
SUBCUTANEOUS
|
|
| MAY CAUSE NAUSEA VOMITING | |
|
3 |
SGLT2I EMPAGLIFLOZIN 10 MG
JARDIANCE
Medicine For DIABETES OBESITY HEART AND KIDNEY PROTECTION |
PO |
1-0-0 |
BEFORE FOOD
|
TILL NEXT VISIT |
| MAY CAUSE GENITOURINARY INFECTIONS | |
|
| |
|
|
|
| Refill :
0 / Substitution: |
|
|
| Education |
: |
| Next Visit |
: 25/Jun/2026 |
| Tests Suggested For Next Visit |
: FUNDUS PHOTOGRAPH |
| |
|
| |
|
|
